COLUMBUS, Ohio–( BUSINESS WIRE )–Forge Biologics (“Forge”), a leading genetic medicine manufacturer, announces a “novel role for adenovirus L4 region 22K and 33K proteins in adeno-associated virus production.” It was announced today that the paper ‘(A novel role for the adenovirus L4 region 22K and 33K proteins in adeno-associated virus production)’ was published through peer-review in ‘Human Gene Therapy’. This paper is from Forge’s Molecular Development team led by Dr. David Dismuke, Chief Technology Officer, Dr. Linas Padegimas, Senior Director of Molecular Development, and Dr. Angela Adsero, Molecular Development Scientist II. Written by a team of scientists.
AAV production requires specific adenoviral genes. However, new genes, especially those that have not yet been discovered, have been overlooked because they share DNA sequences with gene regulatory regions that determine when and how much proteins are made from genes. Using molecular techniques, the Forge scientific team decoupled the dual-purpose nature of this sequence and demonstrated that the previously overlooked L4 region 22K protein is an additional requirement for AAV vector production. This study also suggests that the L4 region 33K protein is important for increasing AAV production.
“Forge is committed to improving gene therapy manufacturing through scientific innovation,” said Dr. David Dismucke, Forge’s Chief Technology Officer. “Discovering these important AAV production requirements will allow us to create more targeted and efficient production strategies. “As the possibility arose, our IP portfolio was strengthened,” he said. He added, “I am very proud of the work of the Forge team as they continue to advance the field of gene therapy by understanding the essential elements of AAV production.”
The paper’s lead author is Dr. Angela Adsero, and contributing authors include the following Forge Molecular Development scientists: Brendan Chestnut, M.Sc, Sara Shahnejat-Bushehri, Ph.D., Lalita Sasnoor, Ph.D, Travis McMurphy, Ph.D .), Michael Swenor, Ryan Pasquino, Arun Pradhan, Ph.D., Victor Hernandez, Ph.D., Linas Padegimas , David Dismucke The full research paper is available through open access here (https://www.liebertpub.com/doi/10.1089/hum.2023.146) can be found here.
“These exciting findings will have significant implications for gene therapy manufacturing globally,” said Robert Kotin, Ph.D., a leading AAV and gene therapy manufacturing leader and member of Forge’s Scientific and Manufacturing Advisory Board. “It could lead to the creation of genetic medicines that have the potential to improve and revolutionize the lives of millions of patients suffering from genetic diseases,” he said. “The Forge team has deep roots in genetic medicine development and vector manufacturing, and the results of this study are proof of that.” He said.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutic development company focused on increasing access to life-changing gene therapies. Forge was founded in 2020 and is headquartered in the Cell and Gene Therapy Hub in Columbus, Ohio, USA. The Hearth, a 200,000-square-foot facility, is a dedicated AAV manufacturing facility with 20 custom-designed cGMP suites. We provide scalable, end-to-end manufacturing services, including process and assay development, cGMP viral vector manufacturing, final fill, plasmid DNA manufacturing, as well as regulatory consulting support to accelerate gene therapy programs from preclinical to clinical and commercial stage manufacturing. Forge aims to accelerate the timeline for innovative medicines for patients with genetic diseases. Website: www.forgebiologics.com
This press release is a translation of the original text written in the company’s preferred language into Korean. Therefore, in order to confirm the accuracy of the translation, it is necessary to go through the original text comparison process. Only the original text originally written is recognized as an announcement with official effect, and all legal liability is valid only for the original text.
View the English version of this press release
This news is a press release written and published by the provider.
Newswire strives to confirm the transparency of the provider and eliminate errors in news content.
You can subscribe for free to press releases from this company and areas of interest via email and RSS. Subscribe >
News provided by Forge Biologics
2023-12-13 02:10:00
#Forge #Biologics #Announces #Paper #Discovery #Transforming #Fundamental #Understanding #Human #Gene #Therapy
